These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9678436)

  • 1. Multiple electrolyte abnormalities after pamidronate administration.
    Elisaf M; Kalaitzidis R; Siamopoulos KC
    Nephron; 1998; 79(3):337-9. PubMed ID: 9678436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Kutluk T; Akyüz C; Yalçin B; Varan A; Büyükpamuküçu M
    Med Pediatr Oncol; 1998 Jul; 31(1):39. PubMed ID: 9607431
    [No Abstract]   [Full Text] [Related]  

  • 3. Electrolyte abnormalities with zoledronic acid therapy.
    Sorscher SM
    Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
    [No Abstract]   [Full Text] [Related]  

  • 4. A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
    Clark SL; Nystrom EM
    J Pharm Pract; 2016 Apr; 29(2):172-6. PubMed ID: 26739479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
    Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
    J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
    De Schepper J; de Pont S; Smitz J; De Coster D; Schots R; Otten J
    Eur J Pediatr; 1999 Sep; 158(9):765-6. PubMed ID: 10485313
    [No Abstract]   [Full Text] [Related]  

  • 7. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy.
    Kadar E; Rush JE; Wetmore L; Chan DL
    J Am Anim Hosp Assoc; 2004; 40(1):75-81. PubMed ID: 14736909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the medical treatment of hypercalcemia of malignancy.
    Hall TG; Schaiff RA
    Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era.
    Isnard Bagnis C; Du Montcel ST; Fonfrede M; Jaudon MC; Thibault V; Carcelain G; Valantin MA; Izzedine H; Servais A; Katlama C; Deray G
    Nephron Physiol; 2006; 103(3):p131-8. PubMed ID: 16557032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyselectrolytemias after single dose of pamidronate administration.
    Panday K; Kanth R
    J Nepal Health Res Counc; 2012 Jan; 10(1):73-5. PubMed ID: 22929643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin.
    Mathur M; Sykes JA; Saxena VR; Rao SP; Goldman GM
    Pediatr Crit Care Med; 2003 Apr; 4(2):252-5. PubMed ID: 12749663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively.
    Bishop NJ; Ninkovic M; Alexander GJ; Holmes SD; Milligan T; Price C; Compston JE
    Clin Sci (Lond); 1999 Aug; 97(2):157-63. PubMed ID: 10409470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.
    Kunin M; Kopolovic J; Avigdor A; Holtzman EJ
    Nephrol Dial Transplant; 2004 Mar; 19(3):723-6. PubMed ID: 14767032
    [No Abstract]   [Full Text] [Related]  

  • 18. Electrolyte abnormalities in patients with chronic renal failure receiving parenteral nutrition.
    Duerksen DR; Papineau N
    JPEN J Parenter Enteral Nutr; 1998; 22(2):102-4. PubMed ID: 9527968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Circadian fluctuations in bivalent electrolytes, calcitonin and parathyroid hormone in the serum of healthy subjects].
    Bagdasarian RA; Burshteĭn GE; Badalian AG; Avakian SA
    Fiziol Cheloveka; 1991; 17(1):145-9. PubMed ID: 1860569
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.